Biogen Uses its Own Superspreader Event to Aid COVID-19 Research

A blood biobank allows scientists to study the immune responses to the coronavirus among infected Biogen employees and their contacts.

Written byClaire Jarvis
| 3 min read
biogen biobank coronavirus covid-19 sars-cov-2 pandemic superspreader superspreading event antibodies neutralizing titers

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

ABOVE: COURTESY BIOGEN

In late February, as the first cases of COVID-19 were detected in the US, the biotech company Biogen became an unwitting superspreader. More than 100 Biogen leaders and executives had attended a leadership meeting in Massachusetts on February 26 and 27. When the executives flew home—to Europe, Asia, and across the US—they spread SARS-CoV-2 to their families and coworkers, seeding new outbreaks. According to the official count, 99 people living in Massachusetts alone were infected with SARS-CoV-2 as a result of the Biogen meeting. The total number of people infected in the US and around the world is higher.

The company chose to capitalize on its early COVID-19 misfortune by helping others with their research. “Several Biogen employees, who at the time were still recovering from COVID-19, began to consider ways they could offer their own anonymized medical information to research efforts,” explains Maha Radhakrishnan, the chief ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • claire jarvis

    Claire Jarvis a science and medical writer based in Atlanta who contributes to The Scientist. With a research background in chemistry, she has covered the latest scientific and medical advances for Chemical & Engineering NewsChemistry WorldUndarkPhysics Today, and OneZero.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies